Yongin, South Korea

Euihan Jung

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Korea Advanced Institute of Science and Technology. Active years: 2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Euihan Jung. Retrieved from https://idiyas.com/inventor/euihan-jung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Euihan Jung, Pioneering RNA-specific Binding Antibody

Introduction:

Euihan Jung, a remarkable inventor based in Yongin-si, South Korea, is making waves in the field of biotechnology with his groundbreaking work. With a patent for an RNA-specific binding antibody under his belt, Jung is revolutionizing the way we detect and treat BC200 RNA-associated diseases.

Latest Patents:

Jung's notable patent is for an antibody that specifically targets BC200 RNA, along with its encoding polynucleotide, detection method, and applications in diagnosing, preventing, and treating BC200 RNA-related illnesses. This innovative approach holds significant promise for the medical community worldwide.

Career Highlights:

Currently affiliated with the prestigious Korea Advanced Institute of Science and Technology (KAIST), Jung is at the forefront of cutting-edge research and development. His dedication to advancing biomedical science is evident in his contributions to the field.

Collaborations:

Jung collaborates closely with esteemed colleagues such as Younghoon Lee and Jung Min Lee, pooling their expertise to push the boundaries of scientific discovery. Together, they form a dynamic team driving innovation in biotechnology.

Conclusion:

In conclusion, Euihan Jung stands out as a visionary inventor with a passion for developing solutions that address pressing healthcare challenges. His work on RNA-specific binding antibodies represents a significant milestone in the quest for more effective diagnostics and treatments. We eagerly anticipate what groundbreaking innovations Jung will unveil next.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…